AZN AstraZeneca PLC

$AZN $JNJ $SLS Part 2. Everyone here is so fixated with the victory lap booth size that they forgot that $SLS quiet period just passed 3 months this week. $SLS didn’t renew the lease for another year to 2028 like they have been doing every year since inception. Remember under strict NDA they don’t need to disclose anything right before a BO. You all can read about it in the final 10k. $SLS GPS Breakthrough Success is a forgone conclusion. My money is on $JNJ perfect fit for both GPS and SLS009. ✌️🙏❤️‍🩹

$ SLS $AZN $BMY $JNJ a fake pump bot the bogus billionaire biostatistician pumps are all a set up for another short rug pull when the 80th is announced kalshi odds 100% on lying pos, tony the tiger will be so scared he's gonna sell it all After the 80th

AstraZeneca is considering entering the cancer vaccine market, exploring one of oncology’s most active research areas as pharmaceutical companies investigate new ways to prevent tumors from returning and treat different forms of cancer. CEO Pascal Soriot told analysts at the European Society for Medical Oncology conference in Madrid that cancer vaccines have been the subject of extensive internal discussions. Soriot said AstraZeneca’s research and development team has made significant progress in mRNA technology over the past several years, giving the company confidence that it could develop meaningful opportunities in the field. He added that further details could emerge over the coming months and years. The British drugmaker has previous vaccine experience through its COVID-19 vaccine developed with Oxford University, although its core focus remains cancer treatments, cardiometabolic diseases and rare conditions. $AZN

$AZN $ORCL $SPY Oracle with 683billion revenue backlog and continue to generate new revenue streams via Ai

$AZN AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care."

$AZN | ASTRAZENECA PLC Q3 2026 EARNINGS HIGHLIGHTS ◆ EPS: $2.79 vs. $2.60 est. ✅ ◆ Revenue: $16.21B vs. $16.00B est. ✅ ◆ Operating Income: $4.39B (+22.0% YoY) ◆ Core Operating Income: $5.86B (+17.0% YoY) ◆ R&D Expense: $3.89B (+6.0% YoY) ◆ SG&A Expense: $5.11B (+0.0% YoY) Key Metrics: ◆ Core Operating Margin expanded 4pp at CER to 36% in Q3 2026, driven by positive product mix and operating leverage. ◆ Reported Operating Margin was 27%, up 3pp year-on-year, with reported operating profit up 22%. ◆ AstraZeneca invested $2.0BN in Summit Therapeutics in October, acquiring roughly 12% of outstanding common stock. Forward Guidance: ◆ FY 2026 Total Revenue expected to increase by a mid-to-high single-digit percentage at CER. ◆ FY 2026 Core EPS expected to increase by a low double-digit percentage at CER. ◆ FY 2026 Core Tax rate expected to be between 18-22%. ◆ FX tailwind: if October-December 2026 rates hold at September 2026 averages, Total Revenue benefits from a low single-digit percentage positive impact vs. CER.

AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat $AZN https://stocktwits.com/news/equity/markets/astra-zeneca-ceo-sees-over-20b-potential-from-2027-drug-trial-readouts-azn-stock-eyes-breakout/cZUhAwOR9Th

$AZN multiple headline here this weekend. Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 TAGRISSO plus savolitinib extended median overall survival by nearly five months TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO "Positive results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)."

$AZN AstraZeneca’s Zegfrovy demonstrated a 46% overall response rate in a trial supporting its accelerated FDA approval, as the company seeks clearance to use the lung cancer drug as a first-line treatment.

$AZN FDA grants Ultomiris accelerated US approval in IgA nephropathy, fifth indication. 🏢 UK drugmaker AstraZeneca's Alexion unit sells Ultomiris, a C5 complement inhibitor ⚠️ It has not been established that it slows kidney function decline; continued approval may hinge on eGFR at week 106 🏢 AZN is worth about $261.10B at $168.45 (16:00 ET, Oct 21, 2026) ✅ Basis: 43.4% placebo-adjusted proteinuria cut at week 34; IgAN affects 200,000+ people in the US 📅 Next: Late-breaking I CAN data at Kidney Week, 23 October 2026 Source: AstraZeneca SEC 6-K, Oct 22

$AZN Astrazeneca. This is such a good hedge against tech stocks. When they tumble this usually goes higher.

$AZN listened to most of the call this morning while on the road. Company loaded not only with a stacked pipeline of drugs but with leadership with vision and strong execution skills. Would not be surprised with this hitting 250 plus in 2027.

AstraZeneca Launches Targeted Lung Cancer Drug In US After FDA Accelerated Approval $AZN https://stocktwits.com/news/equity/markets/astra-zeneca-launches-targeted-lung-cancer-drug-in-us-after-fda-accelerated-approval/cZxwOcyRBDG

AstraZeneca received accelerated FDA approval for Ultomiris to treat adults with immunoglobulin A nephropathy (IgAN), a rare kidney disease that can progressively damage renal function and lead to kidney failure. The approval was based on an interim analysis of a late-stage clinical trial, in which Ultomiris reduced proteinuria—the excess protein in urine—by 43.4% compared with placebo after 34 weeks. The FDA’s accelerated approval allows the treatment to reach eligible patients while additional clinical evidence is collected. The ongoing trial will continue for 106 weeks to determine whether Ultomiris can slow the decline in kidney function, a key outcome needed to support traditional approval. Regulatory uncertainty remains until longer-term results confirm a meaningful clinical benefit; the FDA could require additional evidence or reconsider the approval if the confirmatory trial fails to demonstrate the expected benefit. $AZN

$AZN Advanced research on certain serious diseases. (High attention on what AstraZeneca currently works on)

📈 $AZN — AstraZeneca Technical Analysis: AZN is showing a strong rebound after yesterday's sharp sell-off. The stock moved from around $155.82 to above $161 today, creating a strong bullish recovery candle. The key near-term resistance zone is around $162–$164. A clean breakout above this area, supported by increasing volume, could open the door toward $166–$168. Volume is important here: today's move is bullish, but confirmation with stronger-than-average volume would make the setup considerably stronger. 🤖 AI View: Bullish Recovery 🎯 SST Score: 82/100 — BULLISH Potential setup: Entry: $161–$163 after confirmation Target 1: $166 Target 2: $168–$170 Stop: Below $157.50 AI signal: 🟢 BULLISH — breakout confirmation preferred

🚀 STOCKS TO WATCH TODAY! 🚀 🔥 4 STOCKS ON OUR RADAR 📈 $AZN – AstraZeneca A major pharmaceutical player with strong long-term growth potential. Keep an eye on bullish momentum and a possible continuation move. 📈 $AXSM – Axsome Therapeutics An interesting biotech growth stock. Watch for increasing volume, momentum expansion and a potential breakout. 📈 $ARGX – argenx A strong player in the biotech sector. Monitor price action for renewed buying pressure and a possible bullish continuation. 📈 $AZN | $AXSM | $ARGX 🎯 SST Trading Strategy: We focus on short-term swing trading opportunities, targeting potential moves over the next 3–5 trading days. ✅ Watch for strong BUY signals ✅ Confirm momentum with volume ✅ Identify breakout opportunities ✅ Always manage risk with a stop-loss Structure, not emotion. Trade smart with SST! 🐂 #StocksToWatch #StockMarket #SwingTrading #DayTrading #StockSignals #BiotechStocks #AstraZeneca #AXSM #ARGX #SST

$AZN What the Hell…….When are you coming to Cytovia, Immune Pharmaceuticals and Maxim Pharmaceuticals to clean up my rights with Oakpoint? I don’t care what device you use. I know where you stashed the candy rights. You can’t hide from this crazy nutbag. Are you done circle jerking with my rights? Can you make this fucking deal happen already. You bought my shit in BK and now it’s time for the Legacy share residual rights ( consideration rights / contractual rights ) to be acknowledged. I don’t care what the fuck your planning in 2030. I want my fucking money. Use Satellos. Use ICO Therapeutics. However you want to do it. Pick a pure play. I feel Mr. Marc de Garidel is doing some dirty shit for you people again weaving amongst those assets. It’s obvious you like our goods. Nice. But stop peering in the windows. Get in that room and fuck a shell. Thank you very much. Now finish the deal you Russian Beaver. Stop chopping the wood and build some shit. Ck